Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Moodys
McKinsey
Medtronic
AstraZeneca

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Lirilumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Lirilumab: Sponsors, patents, clinical trial progress

Lirilumab is an investigational drug.

There have been 12 clinical trials for Lirilumab. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2016.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Bristol-Myers Squibb, M.D. Anderson Cancer Center, and Innate Pharma.

There are five US patents protecting this investigational drug and fifty-five international patents.

Recent Clinical Trials for Lirilumab
TitleSponsorPhase
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerBristol-Myers SquibbPhase 1
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerPrECOG, LLC.Phase 1
Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and NeckBristol-Myers SquibbPhase 2

See all Lirilumab clinical trials

Clinical Trial Summary for Lirilumab

Top disease conditions for Lirilumab
Top clinical trial sponsors for Lirilumab

See all Lirilumab clinical trials

US Patents for Lirilumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lirilumab   See Pricing Methods and compositions for treating conditions associated with an abnormal inflammatory responses First Wave Bio, Inc. (Ann Arbor, MI)   See Pricing
Lirilumab   See Pricing Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   See Pricing
Lirilumab   See Pricing Disease therapy by inducing immune response to Trop-2 expressing cells IBC Pharmaceuticals, Inc. (Morris Plains, NJ)   See Pricing
Lirilumab   See Pricing LPT-723 and immune checkpoint inhibitor combinations and methods of treatment Biomed Valley Discoveries, Inc. (Kansas City, MO)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lirilumab

Drugname Country Document Number Estimated Expiration Related US Patent
Lirilumab Australia 2016315852 2035-09-01   See Pricing
Lirilumab Canada 2997136 2035-09-01   See Pricing
Lirilumab Chile 2018000559 2035-09-01   See Pricing
Lirilumab China 109562137 2035-09-01   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
AstraZeneca
Express Scripts
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.